EUVIMEDEUVIMED entdecken
Open Access

A Framework for Exception From Informed Consent in Trials Enrolling Patients With ST‐Segment–Elevation Myocardial Infarction and Cardiogenic Shock

Graham Nichol iD, Neal W Dickert iD, Jacob E Moeller iD, Judith S Hochman iD, Carie Facemire iD, Karen N Adams iD, Gregg W Stone iD, David A Morrow iD, Holger Thiele iD, Timothy D Henry iD, Chuck Simonton, Sunil V Rao iD und 8 weitere

Journal of the American Heart Association · 2025

DOI: 10.1161/jaha.124.037946 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Heart Association, 2025. Verfasst von Graham Nichol und 19 weiteren Autor:innen. Beteiligte Einrichtung: University of Washington-Harborview Center for Prehospital Emergency Care Seattle WA. Hauptthemen laut MEDLINE: Clinical Trials as Topic, Informed Consent, Patient Selection, Shock, Cardiogenic. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 91 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cardiogenic shock (CS) is critical end‐organ hypoperfusion attributable to reduced cardiac output. Acute ST‐segment–elevation myocardial infarction with CS (AMI‐CS) has high mortality. Clinical research is challenging in such patients as they often cannot provide consent, lack available legal representatives, and require initiation of therapy. Multiple trials have enrolled patients with AMI‐CS outside the United States under deferred consent. Trials in the United States have enrolled patients with out‐of‐hospital cardiac arrest under exception from informed consent (EFIC). However, AMI‐CS has a longer therapeutic window to initiate treatment than out‐of‐hospital cardiac arrest, and more patients or their representatives can engage in treatment decisions. We provide a rationale for how a trial enrolling patients with AMI‐CS could qualify for conduct using EFIC by meeting each criterion specified in US human subject regulations. AMI‐CS is a life‐threatening situation, available treatments are unsatisfactory, and collection of valid evidence is necessary. Obtaining informed consent is often not feasible, and trial participation could benefit subjects. Only enrolling consented patients is impracticable and could reduce the study's generalizability. We propose a therapeutic window of 30 minutes within the study intervention must be initiated, with consent sought within 15 minutes, respecting any refusal or objection to enrollment, and otherwise enrollment under EFIC. A trial could enroll patients with AMI‐CS under EFIC and can involve both patients and their representatives. Successful use of EFIC in trials of other interventions in patients with CS or enrolling patients with other acute cardiovascular conditions could increase the available evidence base to improve care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Clinical Trials as TopicInformed ConsentPatient SelectionShock, CardiogenicST Elevation Myocardial InfarctionHumansUnited States

Stichwörter der Autor:innen

acute myocardial infarctioncardiogenic shockemergency researchexception from informed consentrandomized trials

Autor:innen und Institutionen

  • University of Washington-Harborview Center for Prehospital Emergency Care Seattle WA.
  • Emory University School of Medicine Atlanta GA.
  • Department of Cardiology Copenhagen University Hospital-Rigshospitalet Copenhagen Denmark.
  • Cardiovascular Clinical Research Center NYU Grossman School of Medicine New York NY.
  • Abiomed Inc, Johnson and Johnson MedTech Danvers MA.
  • Zena and Michael A. Wiener Cardiovascular Institute Icahn School of Medicine at Mount Sinai New York NY.

ORCID-Profile: Graham Nichol, Neal W Dickert, Jacob E Moeller, Judith S Hochman, Carie Facemire, Karen N Adams, Gregg W Stone, David A Morrow, Holger Thiele, Timothy D Henry, Sunil V Rao, William O'Neill, Ian Gilchrist, Alastair Proudfoot, Ron Waksman, Nick E J West

Zitieren

APA

Nichol, G., Dickert, N. W., Moeller, J. E., Hochman, J. S., Facemire, C., Adams, K. N., Stone, G. W., Morrow, D. A., Thiele, H., Henry, T. D., Simonton, C., Rao, S. V., O'Neill, W., Gilchrist, I., Egelund, R., Proudfoot, A., Waksman, R., West, N. E. J., Sapirstein, J. S., & Krucoff, M. W. (2025). A Framework for Exception From Informed Consent in Trials Enrolling Patients With ST‐Segment–Elevation Myocardial Infarction and Cardiogenic Shock. Journal of the American Heart Association. https://doi.org/10.1161/jaha.124.037946

Vancouver

Nichol G, Dickert NW, Moeller JE, Hochman JS, Facemire C, Adams KN, et al. A Framework for Exception From Informed Consent in Trials Enrolling Patients With ST‐Segment–Elevation Myocardial Infarction and Cardiogenic Shock. Journal of the American Heart Association. 2025. doi:10.1161/jaha.124.037946

BibTeX
@article{Nichol2025,
  author = {Nichol, Graham and Dickert, Neal W and Moeller, Jacob E and Hochman, Judith S and Facemire, Carie and Adams, Karen N and Stone, Gregg W and Morrow, David A and Thiele, Holger and Henry, Timothy D and Simonton, Chuck and Rao, Sunil V and O'Neill, William and Gilchrist, Ian and Egelund, Ryan and Proudfoot, Alastair and Waksman, Ron and West, Nick E J and Sapirstein, John S and Krucoff, Mitchell W},
  title = {A Framework for Exception From Informed Consent in Trials Enrolling Patients With ST‐Segment–Elevation Myocardial Infarction and Cardiogenic Shock},
  journal = {Journal of the American Heart Association},
  year = {2025},
  doi = {10.1161/jaha.124.037946}
}
Kostenlos starten →